Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Multi-center, Phase II Fixed Dose Study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Brief Summary: The purpose of this clinical research study is to compare the best overall response rate (BORR)(as per modified WHO criteria) in patients with previously treated, therapy-refractory, or -intolerant, Stage III (unresectable) or Stage IV melanoma receiving ipilimumab doses of 0.3, 3, and 10 mg/kg. The safety of this product will also be evaluated.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: ipilimumab (MDX-010, BMS-734016) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab | Intervention Type: DRUG; Name: ipilimumab (MDX-010, BMS-734016); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): 3
B: Arm Label: vemurafenib + cobimetinib + atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib, Drug: Cobimetinib, Drug: Atezolizumab | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): vemurafenib + cobimetinib + atezolizumab | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): vemurafenib + cobimetinib + atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): vemurafenib + cobimetinib + atezolizumab
C: Arm Label: Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: MEL: Pembrolizumab 10 mg/kg Q2W (Part B); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 2 mg/kg Q3W (Part E-Not Enrolled); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 5 mg/kg Q3W (Part E-Not Enrolled); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 10 mg/kg Q3W (Part E-Not Enrolled); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): MEL: Pembrolizumab 10 mg/kg Q2W (Part B), MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D), MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D), NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F), NSCLC: Pembrolizumab 10 mg/kg Q3W (Part E-Not Enrolled), NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F), NSCLC: Pembrolizumab 2 mg/kg Q3W (Part E-Not Enrolled), NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F), NSCLC: Pembrolizumab 5 mg/kg Q3W (Part E-Not Enrolled), Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A), Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1), Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A), Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2), Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2), Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Domatinostat, Drug: Nivolumab | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Domatinostat, Drug: Nivolumab | Arm Label: D; Type: EXPERIMENTAL; Interventions: Drug: Domatinostat, Drug: Nivolumab, Drug: Ipilimumab | Intervention Type: DRUG; Name: Domatinostat; Assigned to Arm(s): B, C, D | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): A, B, C, D | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): D

Answer: A